Synergistic induction of apoptosis in primary B-CLL cells after treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand and histone deacetylase inhibitors

Journal of Oncology

Volumn , Issue , 2009, Pages

  Griffith, Thomas S ^a   Norian, Lyse A ^a   Kucaba, Tamara A ^a   Earel, James K ^a   Knutson, Tina ^a   Vanoosten, Rebecca L ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DRUG VEHICLE; HISTONE DEACETYLASE INHIBITOR; OXAMFLATIN; PROTEIN BCL 2; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TRICHOSTATIN A; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CELL TRANSFORMATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 68349090436     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2009/408038     Document Type: Article

References (37)

1. Griffith T. S., Lynch D. H., TRAIL: a molecule with multiple receptors and control mechanisms Current Opinion in Immunology 1998 10 5 559 563
2. Wiley S. R., Schooley K., Smolak P. J., Identification and characterization of a new member of the TNF family that induces apoptosis Immunity 1995 3 6 673 682
3. Kelley S. K., Ashkenazi A., Targeting death receptors in cancer with Apo2L/TRAIL Current Opinion in Pharmacology 2004 4 4 333 339
4. Pan G., ORourke K., Chinnaiyan A. M., The receptor for the cytotoxic ligand TRAIL Science 1997 276 5309 111 113
5. Pan G., Ni J., Wei Y.-F., Yu G.-I., Gentz R., Dixit V. M., An antagonist decoy receptor and a death domain-containing receptor for TRAIL Science 1997 277 5327 815 818
6. Sheridan J. P., Marsters S. A., Pitti R. M., Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors Science 1997 277 5327 818 821
7. Walczak H., Degli-Esposti M. A., Johnson R. S., TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL The EMBO Journal 1997 16 17 5386 5397
8. Chinnaiyan A. M., Tepper C. G., Seldin M. F., FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis The Journal of Biological Chemistry 1996 271 9 4961 4965
9. Bodmer J.-L., Holler N., Reynard S., TRAIL receptor-2 signals apoptosis through FADD and caspase-8 Nature Cell Biology 2000 2 4 241 243
10. Kischkel F. C., Lawrence D. A., Chuntharapai A., Schow P., Kim K. J., Ashkenazi A., Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5 Immunity 2000 12 6 611 620
11. Reed J. C., Mechanisms of apoptosis The American Journal of Pathology 2000 157 5 1415 1430
12. Sprick M. R., Weigand M. A., Rieser E., FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2 Immunity 2000 12 6 599 609
13. Hajra K. M., Liu J. R., Apoptosome dysfunction in human cancer Apoptosis 2004 9 6 691 704
14. Johnson C. R., Jarvis W. D., Caspase-9 regulation: an update Apoptosis 2004 9 4 423 427
15. Ashkenazi A., Holland P., Eckhardt S. G., Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL) Journal of Clinical Oncology 2008 26 21 3621 3630
16. LeBlanc H. N., Ashkenazi A., Apo2L/TRAIL and its death and decoy receptors Cell Death and Differentiation 2003 10 1 66 75
17. Rozman C., Montserrat E., Chronic lymphocytic leukemia The New England Journal of Medicine 1995 333 16 1052 1057
18. Hamblin T. J., Oscier D. G., Chronic lymphocytic leukaemia: the nature of the leukaemic cell Blood Reviews 1997 11 3 119 128
19. MacFarlane M., Harper N., Snowden T. R., Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia Oncogene 2002 21 44 6809 6818
20. Bolden J. E., Peart M. J., Johnstone R. W., Anticancer activities of histone deacetylase inhibitors Nature Reviews Drug Discovery 2006 5 9 769 784
21. Rasheed W. K., Johnstone R. W., Prince H. M., Histone deacetylase inhibitors in cancer therapy Expert Opinion on Investigational Drugs 2007 16 5 659 678
22. Jenuwein T., Allis C. D., Translating the histone code Science 2001 293 5532 1074 1080
23. Marks P. A., Rifkind R. A., Richon V. M., Breslow R., Miller T., Kelly W. K., Histone deacetylases and cancer: causes and therapies Nature Reviews Cancer 2001 1 3 194 202
24. Carew J. S., Giles F. J., Nawrocki S. T., Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy Cancer Letters 2008 269 1 7 17
25. vanOosten R. L., Earel J. K. Jr., Griffith T. S., Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity Apoptosis 2007 12 3 561 571
26. vanOosten R. L., Earel J. K. Jr., Griffith T. S., Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors Cancer Gene Therapy 2006 13 6 628 632
27. Fulda S., Modulation of TRAIL-induced apoptosis by HDAC inhibitors Current Cancer Drug Targets 2008 8 2 132 140
28. Rosato R. R., Almenara J. A., Dai Y., Grant S., Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells Molecular Cancer Therapeutics 2003 2 12 1273 1284
29. Inoue S., Mai A., Dyer M. J. S., Cohen G. M., Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis Cancer Research 2006 66 13 6785 6792
30. Earel J. K. Jr., vanOosten R. L., Griffith T. S., Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells Cancer Research 2006 66 1 499 507
31. Karacay B., Sanlioglu S., Griffith T. S., Sandler A., Bonthius D. J., Inhibition of the NF- B pathway enhances TRAIL-mediated apoptosis in neuroblastoma cells Cancer Gene Therapy 2004 11 10 681 690
32. vanOosten R. L., Moore J. M., Karacay B., Griffith T. S., Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/Apo-2L-induced apoptosis by enhancing TRAIL-R2 expression Cancer Biology Therapy 2005 4 10 1104 1112
33. Garofalo M., Romano G., Quintavalle C., Selective inhibition of PED protein expression sensitizes B-cell chronic lymphocytic leukaemia cells to TRAIL-induced apoptosis International Journal of Cancer 2007 120 6 1215 1222
34. Olsson A., Diaz T., Aguilar-Santelises M., Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D Leukemia 2001 15 12 1868 1877
35. Movassagh M., Foo R. S.-Y., Simplified apoptotic cascades Heart Failure Reviews 2008 13 2 111 119
36. Green D. R., Kroemer G., The pathophysiology of mitochondrial cell death Science 2004 305 5684 626 629
37. Keating M. J., Flinn I., Jain V., Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study Blood 2002 99 10 3554 3561